LONDON – A second COVID-19 vaccine has reported positive results in an interim phase III analysis, with Russia’s Sputnik V showing 92% efficacy. Read More
Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) shot 237% higher to $18 Nov. 11 on new top-line results for its targeted antibody, bemarituzumab, in gastric cancer. Read More
Though founded in 2018, Inipharm Inc. has just closed on a $35 million series A financing designed to push its lead program through an IND filing and into the clinic to treat liver-related diseases. Read More
Researchers at the Feinstein Institutes for Medical Research, the research arm of New York-based Northwell Health, illuminated the precise pathway from the brainstem to the spleen that controls inflammation in a study published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS). Essentially, the work demonstrates how scientists could use the vagus nerve to hack the immune system, enabling them to turn down the excessive response that underlies autoimmune disease without the use of biologics or immunosuppressive drugs. Read More
With the next big wave of biologic patent expirations soon to wash over the U.S. market, companies developing biosimilars are optimistic about the future. “We’re at a place where we’re seeing really strong uptake of biosimilars, which has resulted in cost savings,” Chad Pettit, executive director of marketing for Amgen Inc.’s biosimilars unit, told BioWorld. Read More
BioWorld looks at translational medicine, including: Reversal of pumping direction is reversal of fortune for tumor cells; Cholesterol drug affects checkpoint blockade via MHC1; Heart development protein has role in adult immunity. Read More
New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer’s annual meeting Nov. 9-14, including: Bergenbio, Exuma, Genexine, I-Mab, Imcheck, Innovent, Intensity, Jounce, Nektar, Shattuck, Sotio. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AGTC, Ampio, Asieris, Blueberry, Cynata, Deciphera, Edgewise, Five Prime, Gyroscope, Henlius, Lineage, Lumos, Mesoblast, Oncternal, Pfizer, Prilenia, RDIF, Reven, Sagent, Xbrane. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Angiocrine, Bioxcel, Gyroscope, Inventiva, Sebela, Sorrento, Surface. Read More
